Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab with immunomodulator reduces rates of hospitalization among Veterans with IBD

The latest issue of Clinical Gastroenterology & Hepatology reports that dual therapy with infliximab and immunomodulator reduces rates of hospitalization and surgery among Veterans with inflammatory bowel disease.

News image

Effectiveness of early treatment with biologics and immunomodulator therapy on healthcare utilization remains poorly defined.

Dr Neena Abraham and colleagues from Arizona, USA assessed rates of hospitalization and surgery within 1 year after initiation of infliximab and/or immunomodulator therapy in a United States cohort of patients with inflammatory bowel disease.

The researchers conducted a retrospective, observational cohort study of veterans with Crohn’s disease or ulcerative colitis by using administrative data from 176 Department of Veteran Affairs facilities.

Inpatient, outpatient, and death records were linked longitudinally with prescription fill data.

A 50% relative reduction in surgery occurred after 5 months of dual therapy
Clinical Gastroenterology & Hepatology

Each person-day of follow-up was assessed for treatment with infliximab, immunomodulators, both (dual therapy), or neither.

The researchers calculated drug exposure time and used Poisson and logistic regression analyses to assess outcomes.

The team reported that the cohort of 20,474 patients included 8042 patients with Crohn’s disease, and 12,432 with ulcerative colitis prescribed infliximab, immunomodulator, or dual therapy.

Adjusted models revealed 50% relative reductions in hospitalization among patients who received 9 months of immunomodulator monotherapy, 8 months of infliximab, or 7.7 months of dual therapy.

The research team found that a 50% relative reduction in surgery was observed among patients receiving 7 months of infliximab or 5 months of dual therapy.

Analysis of dose-response data revealed 73% and 92% reductions in risk of hospitalization and surgery, respectively, after 9 months of dual therapy.

Dr Abraham's team commented, "On the basis of a retrospective cohort study, dual therapy with infliximab and an immunomodulator for less than 8 months is associated with significant reductions in hospitalization, and surgery within 1 year of the start of therapy."

"These findings indicate that patients with IBD are more likely to benefit if dual therapy is initiated earlier in their first year of therapy."

Clin Gastroenterol Hepatol 2013: 11(10): 1281-1287
02 October 2013

Go to top of page Email this page Email this page to a colleague

 26 May 2016 
Direct-acting antivirals in Hep C cirrhosis
 26 May 2016 
Education booklet for colonoscopy bowel preparation
 26 May 2016 
Uncomplicated diverticulitis in outpatients
 25 May 2016 
Recurrence of Barrett’s after successful endoscopic therapy
 25 May 2016 
Preventing NSAID-associated GI toxicity
 25 May 2016 
PPIs and NSAID-induced small bowel injury
 24 May 2016 
Fecal inflammatory markers in Crohn's
 24 May 2016 
Depression and IBD recurrence
 24 May 2016 
New therapies for NASH
 23 May 2016 
Risk factors for peptic ulcer bleeding outcomes
 23 May 2016 
Liver transplantation for hepatocellular carcinoma
 23 May 2016 
Cancer after colectomy in IBD
 20 May 2016 
Biomarker for colorectal cancer diagnosis
 20 May 2016 
Prognostic score for hepatic venous outflow obstruction
 20 May 2016 
Treatment for uncomplicated acute diverticulitis
 19 May 2016 
Probiotics and H. pylori eradication
 19 May 2016 
Impaired skeletal health in atrophic gastritis
 19 May 2016 
Predicting outcome in ulcerative colitis
 18 May 2016 
Erectile dysfunction in IBD
 18 May 2016 
Surgical fundoplication for GERD 
 18 May 2016 
Acute GERD and esophageal histologic changes
 17 May 2016 
Vitamin D level and clinical status in IBD 
 17 May 2016 
Mucosal dysbiosis in Crohn's disease
 17 May 2016 
Inpatient costs for IBD and acute pancreatitis
 16 May 2016 
Outcomes of postcolonoscopy colorectal cancers
 16 May 2016 
C. difficile in ulcerative colitis patients
 16 May 2016 
Therapy for Crohn's in a Medicaid population
 13 May 2016 
Parkinson's disease and IBD
 13 May 2016 
Non-traditional heart disease risk factors in NAFLD
 13 May 2016 
Inactivated oral cholera vaccine
 12 May 2016 
Gestational diabetes mellitus and NAFLD
 12 May 2016 
Impact of Crohn's in the USA
 12 May 2016 
Ozanimod induction and ulcerative colitis
 11 May 2016 
Anti-TNF discontinuation in IBD
 11 May 2016 
Age and disease presentation with Crohn's disease
 11 May 2016 
Prognosis after colorectal cancer resection
 10 May 2016 
Gluten-free diet in patients with IBS-diarrhea
 10 May 2016 
Noninvasive test for IBD
 10 May 2016 
Digital health for gastroenterology
 09 May 2016 
Diarrheal infections in adults
 09 May 2016 
Quality improvement initiative and readmission for cirrhosis
 09 May 2016 
Coffee or tea and the risk of Barrett's
 06 May 2016 
Risk factors in peptic ulcer bleeding
 06 May 2016 
Recurrent pancreatitis after acute pancreatitis
 06 May 2016 
Managing acute lower GI bleeding
 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 05 May 2016 
Genetics in early-early-onset IBD
 05 May 2016 
Reductions in quality of screening colonoscopies
 04 May 2016 
Anti-TNF therapy for IBD
 04 May 2016 
Bismuth and H. pylori eradication
 04 May 2016 
Chromoendoscopy vs colonoscopy for dysplasia in colitis
 03 May 2016 
Surgery vs medical therapy for GERD
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 02 May 2016 
Genetic variant that increase NAFLD risk
 02 May 2016 
Resection of colorectal polyps
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 29 April 2016 
Crohn's disease associated genes
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
HCV infection in Baby Boomers with Medicare

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us